Cisplatin + S1 + Durvalumab + Durvalumab
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Superior Sulcus Tumor
Conditions
Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III
Trial Timeline
Sep 1, 2020 → Aug 31, 2030
NCT ID
NCT04465968About Cisplatin + S1 + Durvalumab + Durvalumab
Cisplatin + S1 + Durvalumab + Durvalumab is a phase 3 stage product being developed by AstraZeneca for Superior Sulcus Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04465968. Target conditions include Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III.
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04465968 | Phase 3 | Recruiting |